Medicare Plans’ Preferential Coverage For Off-Label Drugs Debated
Executive Summary
A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication